Safety of SGLT-2 inhibitors in the management of heart failure in the adult congenital heart disease patient population
Open Access
- 17 February 2024
- journal article
- Published by Elsevier in International Journal of Cardiology Congenital Heart Disease
- Vol. 15, 100495
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Mechanisms of benefits of sodium-glucose cotransporter 2 inhibitors in heart failure with preserved ejection fractionEuropean Heart Journal, 2023
- Safety and Treatment Experience With Sodium/glucose Cotransporter-2 Inhibitors in Adult Patients With Congenital Heart DiseaseJournal of Cardiac Failure, 2023
- Early changes in estimated glomerular filtration rate post‐initiation of empagliflozin in EMPEROR‐ReducedEuropean Journal of Heart Failure, 2022
- Empagliflozin in Heart Failure with a Preserved Ejection FractionNew England Journal of Medicine, 2021
- Sacubitril/valsartan in the treatment of systemic right ventricular failureHeart, 2021
- Dapagliflozin in Patients with Chronic Kidney DiseaseNew England Journal of Medicine, 2020
- Sodium-Glucose Cotransporter-2 inhibitors are potential therapeutic agents for treatment of non-diabetic heart failure patientsJournal of Cardiology, 2020
- Effect of SGLT2 Inhibitors on the Sympathetic Nervous System and Blood PressureCurrent Cardiology Reports, 2019
- 2018 AHA/ACC Guideline for the Management of Adults With Congenital Heart DiseaseJACC, 2019
- Neurohormonal activation in heart failure with reduced ejection fractionNature Reviews Cardiology, 2016